Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial to Assess the Prophylactic Efficacy and Safety of Sebaloxavir Marboxil Tablets/Oral Suspension for Influenza Prevention in Household Contacts Aged ≥2 Years.

NCT07730346 is registered in ClinicalTrials.gov with Nanjing Zenshine Pharmaceuticals as lead sponsor.

NCT NCT07730346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07730346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial to Assess the Prophylactic Efficacy and Safety of Sebaloxavir Marboxil Tablets/Oral Suspension for Influenza Prevention in Household Contacts Aged ≥2 Years.
Lead sponsor
Nanjing Zenshine Pharmaceuticals
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 7, 2026
Completion date
January 30, 2028
Enrollment
858 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza prevention